BK0476 Gene Sequencing
- 692.882
- +0.291+0.04%
The Three-year Shareholder Returns and Company Earnings Persist Lower as Guangzhou Kingmed Diagnostics Group (SHSE:603882) Stock Falls a Further 9.0% in Past Week
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of Guangzhou Kingmed Diagnost
Jinyu Medical (603882): Affected by the external environment and credit impairment, short-term pressure waits for an upward inflection point in profits
Core view: Jinyu Medical announced the 2023 and 2024Q1 results. In '23, the company achieved revenue of 8.540 billion yuan (-44.82%); net profit to mother of 643 million yuan (-76.64%); after deducting non-payment
Dean Diagnosis (300244): Impairment calculation affects apparent performance First quarter results are lower than expected
Event: The company released its report for the first quarter of 2024. In the first quarter of 2024, it achieved operating income of 2,973 billion yuan (-8.01%), net profit to mother of 0.23 million yuan (-85.54%), deducting non-net profit
American Health (002044): The trend of increasing customer unit prices in 2023 is evident, and performance is growing strongly
Announcement: American Health released its 2023 annual report, 2024 quarterly report, strong growth in 2023 performance, and a significant increase in profitability. 2023 operating income of 10.89 billion yuan (+26.4%), net profit to mother
Shenzhen Gongjin Electronics Co., Ltd. (SHSE:603118) Surges 6.3%; Individual Investors Who Own 48% Shares Profited Along With Insiders
Key Insights Significant control over Shenzhen Gongjin Electronics by individual investors implies that the general public has more power to influence management and governance-related decisions A t
Investors Still Aren't Entirely Convinced By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) Earnings Despite 25% Price Jump
Despite an already strong run, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) shares have been powering on, with a gain of 25% in the last thirty days. Unfortunately, th
Huada Intelligent Manufacturing (688114): Market share of genetic sequencers continues to increase, overseas markets maintain high growth
Key investment events: On the evening of April 25, 2024, the company released its 2023 annual report & 2024 quarterly report. The company's revenue in 2023 was 2,911 billion yuan (-31.19%, in parentheses, same as below)
Da Ren Tang (600329): Outstanding industrial performance, smooth mixed improvement exhibition
Key investment events: Daren Tang released its 2024 quarterly report. During the reporting period, it achieved revenue of 2,086 billion yuan (-3.19% YoY), net profit attributable to mother of 387 million yuan (YoY -3.36%), deducting net profit from non-return to mother3
Express News | Nanjing Xinbai: The controlling shareholder and actual controller received the Securities Regulatory Commission's “Administrative Penalty and Market Ban Decision”
Berry Gene (000710.SZ): No big data artificial intelligence business yet
Gelonghui, April 30 | Berry Gene (000710.SZ) said on the investor interactive platform that the company is committed to the comprehensive transformation of gene sequencing technology to clinical application, focusing on reproductive health, genetic disease testing, tumor testing, scientific and technological services, etc., and there is no big data artificial intelligence business yet.
Berry Gene (000710.SZ): Committed to the comprehensive transformation of gene sequencing technology to clinical application, focusing on reproductive health, genetic disease testing, tumor testing, scientific and technological services
Gelonghui, April 30 | Berry Gene (000710.SZ) said on the investor interactive platform that the company is committed to the comprehensive transformation of gene sequencing technology to clinical application, focusing on reproductive health, genetic disease testing, tumor testing, scientific and technological services; for basic research services, the company has now established dozens of research product types covering library sequencing, animal and plant genome De novo, animal and plant genome re-sequencing, human genome re-sequencing, transcriptional regulation, single-cell transcriptomics, spatial proteomics, microbiology, etc. in cancer research, Genetic disease research, animal and plant research
Da Ren Tang (600329): The Q1 results were generally in line with expectations, and quick price increases led to an increase in gross margin
Incident: The company released its 2024 quarterly report, 2024Q1. The company achieved operating income of 2,086 billion yuan, a year-on-year decrease of 3.19%; net profit to mother was 387 million yuan, a year-on-year decrease of 3.36%; net profit not attributable to mother
Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3%
Tianjin Pharmaceutical Da Ren Tang's (SHA:600329) attributable profit fell 3.4% year over year to 387.3 million yuan in the first quarter, according to a Tuesday filing with the Shanghai Stock Exchang
Huada Intelligent Manufacturing (688114.SH) has repurchased a total of 3.832,400 shares at a cost of 280 million yuan
Huada Intelligent Manufacturing (688114.SH) issued an announcement. As of April 30, 2024, the company approved Shanghai Securities...
Changhong Technology (300151.SZ): Actual controller Li Huanchang has increased his holdings by 127,400 shares more than half of the increase period
Gelonghui, April 30, 丨 Changhong Technology (300151.SZ) announced that as of the disclosure date of this announcement, the plan to increase holdings was over halfway. From February 1, 2024 to April 30, 2024, Mr. Li Huanchang, the controlling shareholder and actual controller of the company, increased his holdings of the company's shares by 127,400 shares through centralized bidding through the Shenzhen Stock Exchange trading system, accounting for 0.02% of the company's total share capital. The increase amount was RMB 1,646,600.
Express News | Zuoli Pharmaceutical: Senior Manager Ma Aihua's Spouse Short-Term Trading Company Shares
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
Jingfeng Pharmaceutical (000908.SZ) announced first-quarter results, net profit of 3.553 million yuan, an increase of 174.14%
Jingfeng Pharmaceutical (000908.SZ) released its report for the first quarter of 2024. The company's revenue was 1.01...
*ST Toyo (002086.SZ) reported first-quarter results with a net loss of 14.3898 million yuan
*ST Toyo (002086.SZ) released its report for the first quarter of 2024. The company achieved revenue during the reporting period...
Huada Intelligent Manufacturing (688114): The gene sequencing business is growing steadily and the global layout continues to deepen
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 2,911 billion yuan (yoy -31.19%) and net profit to mother of -607 million yuan (yoy-1)